Gene-Editing Pioneer CRISPR Therapeutics Worth a Bet Before Year-End? Two Catalysts Await Release

Life Science

Intuitive Surgical Stock Crashes 30%, But Wall Street Isn’t Flinching

Life Science

GLP-1 Concept Stock Amylyx Soars 247% Year-to-Date: How Much Room Remains for Upside?

Life Science

Medtronic Beats Estimates, Raises Full-Year Guidance; Is a Valuation Recovery Underway?

Life Science

Novo Nordisk Faces Competitive Pressure and May Strengthen Its Weight-Loss Pipeline Through Acquisitions

Life Science

Kimberly-Clark’s Merger Acquisition Hangs in the Balance? Market Doubts and Potential Opportunities Coexist

Financial Service, Life Science

Ark Invest Goes Against the Grain: Wood Bets on Nvidia and the Gene-Editing Arena

Life Science

Eli Lilly Is on an M&A Spree—Will the $2.88 Billion Merida Deal Be Enough to Diversify?

Life Science

Viking Therapeutics Is Down 66% — Here’s What Could Bring It Back

Life Science

How to Choose Between Two Major Pharmaceutical Themed ETFs?

Financial Service, Life Science

Rasonque’s Lightning Approval Validates Druckenmiller’s Bet on Revolution Medicines

Life Science

Clinical-Stage Biotechnology Company Biohaven Sees Dual Positive Developments During the Week

Life Science

J&J’s 64-Year Dividend Streak Reinforces ‘Sleep-Well’ Stock Status

Life Science

Novo Nordisk’s Weight-Loss Oral Drug Makes New Progress in China Approval

Life Science

Billionaire Loads Up on Revolution Medicines, the Upside Could Be More Than 7%

Life Science